Dennis Karl Huang is VP at Ultragenyx Pharmaceutical Inc. (RARE). They have made 7 open-market trades across 1 company since 2019, most recently 2026-04-16.
CIK 0001641217
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RARE | 147,845 | $2.5M |
Shares reported on the most recent Form 4, priced at the 2026-04-20 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RARE | SELL | 2023-03-01 | 2023-03-03 | $45.65 | $18K | -10.2% | -10.8% | +9.3% |
| RARE | SELL | 2022-03-01 | 2022-03-03 | $66.62 | $431K | +1.0% | +23.9% | -26.8% |
| RARE | SELL | 2021-10-14 | 2021-10-18 | $81.14 | $29K | +8.5% | -0.8% | -13.4% |
| RARE | SELL | 2021-05-06 | 2021-05-10 | $113.68 | $41K | +7.5% | -9.3% | -13.5% |
| RARE | SELL | 2021-03-01 | 2021-03-03 | $138.18 | $1.2M | +3.2% | -9.5% | -20.3% |
| RARE | SELL | 2020-10-14 | 2020-10-16 | $88.00 | $23K | +2.6% | +28.2% | +51.1% |
| RARE | SELL | 2019-03-05 | 2019-04-17 | $65.52 | $41K | +1.9% | -5.1% | -8.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.